This Article Full Text (PDF) All Versions of this Article: 1534734609331597v1 8/1/11    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Edmonds, M. Search for Related Content PubMed PubMed Citation Articles by Edmonds, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Diabetic Foot Social Bookmarking                         What's this?

Apligraf in the Treatment of Neuropathic Diabetic Foot Ulcers

Diabetic Foot Clinic, King's College Hospital, Denmark Hill, London, United Kingdom, michael.edmonds{at}kch.nhs.uk

European and Australian Apligraf Diabetic Foot Ulcer Study Group

This study compared the efficacy and safety of Apligraf (Organogenesis, Inc., Canton, MA) in combination with standard therapy versus standard therapy alone in the treatment of neuropathic diabetic foot ulcers. Efficacy was assessed by time to complete wound healing (by 12 weeks) and incidence of complete wound closure (at 12 weeks). This was an international multi-center, randomized, controlled study. Patients were eligible for entry into the study if the following criteria were met: type 1 or type 2 diabetes mellitus, age 18 to 80 years, adequate glycemic control, and the presence of a full-thickness neuropathic ulcer for at least 2 weeks prior to the initial screening visit. Following the 2-week screening period, the 2 treatment groups received standard ulcer care consistent with international treatment guidelines that comprised sharp debridement, saline-moistened dressings, and a non—weight bearing regimen. There were 106 subjects screened for enrollment, 82 randomized to the treatment groups, and 72 treated (33 Apligraf subjects and 39 standard therapy subjects) before the study was terminated. Kaplan—Meier curves indicated a trend for shorter time to complete wound healing in the Apligraf group compared with the standard therapy group (p = .059; log-rank test). The median time to healing was 84 days in the Apligraf group, whereas no median time to healing could be determined for the standard therapy group because <50% of the standard therapy subjects healed. By 12 weeks, 51.5% (17/33) Apligraf subjects had achieved complete wound closure compared with 26.3% (10/38) of standard therapy subjects (p = .049; Fisher's exact test). Even though the study was halted prematurely, this study suggested that the use of Apligraf resulted in a higher incidence of wound closure by 12 weeks.

Key Words: ulcer • neuropathy • Apligraf • offloading • healing • diabetes • diabetic foot

This version was published on March 1, 2009

The International Journal of Lower Extremity Wounds, Vol. 8, No. 1, 11-18 (2009)
DOI: 10.1177/1534734609331597


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?